Fraser Symmans
Overview
Explore the profile of Fraser Symmans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, et al.
J Pathol
. 2024 Jan;
262(3):271-288.
PMID: 38230434
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in...
2.
Thagaard J, Broeckx G, Page D, Jahangir C, Verbandt S, Kos Z, et al.
J Pathol
. 2023 Aug;
260(5):498-513.
PMID: 37608772
The clinical significance of the tumor-immune interaction in breast cancer is now established, and tumor-infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple-negative (estrogen receptor,...
3.
Page D, Broeckx G, Jahangir C, Verbandt S, Gupta R, Thagaard J, et al.
J Pathol
. 2023 Aug;
260(5):514-532.
PMID: 37608771
Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized...
4.
Wulfkuhle J, Yau C, Wolf D, Vis D, Gallagher R, Brown-Swigart L, et al.
JCO Precis Oncol
. 2020 Sep;
2.
PMID: 32914002
Purpose: In the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2), the pan-erythroblastic oncogene B inhibitor neratinib was available to...
5.
Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, et al.
Int J Mol Sci
. 2020 Feb;
21(4).
PMID: 32085669
Circulating microRNA (ct-miRNAs) are able to identify patients with differential response to HER2-targeted therapy. However, their dynamics are largely unknown. We assessed 752 miRNAs from 52 NeoALTTO patients with plasma...
6.
Dieci M, Radosevic-Robin N, Fineberg S, Van den Eynden G, Ternes N, Penault-Llorca F, et al.
Semin Cancer Biol
. 2017 Oct;
52(Pt 2):16-25.
PMID: 29024776
Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are...
7.
Wolf D, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, et al.
NPJ Breast Cancer
. 2017 Sep;
3:31.
PMID: 28948212
Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. However,...
8.
Hendry S, Salgado R, Gevaert T, Russell P, John T, Thapa B, et al.
Adv Anat Pathol
. 2017 Aug;
24(6):311-335.
PMID: 28777143
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different...
9.
Hendry S, Salgado R, Gevaert T, Russell P, John T, Thapa B, et al.
Adv Anat Pathol
. 2017 Aug;
24(5):235-251.
PMID: 28777142
Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However,...
10.
Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, et al.
Breast Cancer Res
. 2017 May;
19(1):55.
PMID: 28490348
Background: Accurate determination of the predictive markers human epidermal growth factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor (PgR/PGR), and marker of proliferation Ki67 (MKI67) is indispensable for therapeutic...